Delivery of Therapeutic Proteins

The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethyl...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2010-06, Vol.99 (6), p.2557-2575
Main Authors: Pisal, Dipak S., Kosloski, Matthew P., Balu-Iyer, Sathy V.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Chemistry, Pharmaceutical
General pharmacology
Half-Life
Humans
hyperglycosylation
liposomes
Liposomes - pharmacokinetics
Medical sciences
Microspheres
Nanoparticles - chemistry
PEGylation
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
poly(lactic/glycolic) acid
Polyethylene Glycols - chemistry
Polymers - chemistry
protein delivery
Proteins - administration & dosage
Sialic Acids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethylene glycol) (PEG), polysialic acid, or glycolic acid, as well as developing new formulations containing nanoparticulate or colloidal systems (e.g., liposomes, polymeric microspheres, polymeric nanoparticles). Such strategies have the potential to develop as next generation protein therapeutics. This review includes a general discussion on these delivery approaches.
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.22054